Navigation Links
Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
Date:5/20/2008

to play an important role in inflammation, as well as cancer cell proliferation, apoptosis and metastasis. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system (CNS) side effects. The Company is also investigating a second generation MEK inhibitor, RDEA436, for potential use in inflammatory diseases and cancer. Preclinical data suggest that RDEA436 is a potent in vitro and in vivo inhibitor of MEK and may have favorable properties, such as low CNS penetration. In addition, RDEA436 has demonstrated a long half-life in a human micro-dose pharmacokinetic study, with the potential for once daily dosing in humans.

About Ardea Biosciences

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
2. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
3. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
4. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
11. Neurocrine Biosciences Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Cardinal Health will today name ... winners of its prestigious Independent Pharmacy Best Practices Competition, ... of the nation,s largest gatherings of independent pharmacists. ... pharmacies from Ohio , ... – were selected for implementing exceptionally creative methods that ...
(Date:7/25/2014)... July 25, 2014 According to ... "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Share, Growth, Trends and Forecast (Value and Volume), 2013 ... USD 19.99 billion in 2012 and is expected to ... 2019 to reach USD 32.24 billion in 2019. ...
(Date:7/25/2014)... Laboratories, Inc. (NASDAQ: IDXX ) today reported ... 11% versus the prior year period to $390 million. ... of 2014 versus the prior year period was 9%, ... . Earnings per diluted share ("EPS") for the quarter ... year period to $1.10."In the second quarter, we continued ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28
... Study Reveals that Thoracic Endoluminal Grafting is a Feasible Alternative ... TO Open Surgical Repair, J Vasc Surg. 2007 Sep; 46(3):413-20. ... JA, Olsen DM, Shtutman A, Lucas LA, Wheatley G, Alpern J, Ramaiah V, Diethrich ... ...
... The National Institute of,Standards and Technology (NIST) ... in the Commerce Department,s Advanced Technology Program,(ATP), a ... awarded to the early-phase Michigan biotechnology company developing,drug ... and,other bone disorders. Velcura scientists have discovered ...
Cached Medicine Technology:Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies 2Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies 3Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies 4Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies 5Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies 6NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease 2
(Date:7/25/2014)... 2014 On July 22, 2014, ... client and the nation’s number one provider of ... announced their partnership with TransAct Merchant Solutions’ National ... ISO/MSP of Chase Paymentech Solutions, LLC, which provides ... Companies that are members of TransAct’s National Association ...
(Date:7/25/2014)... 25, 2014 This is a ... of the Galactooligosaccharides (GOS) industry in Global ... of the industry, including definitions, applications and industry ... market analysis are provided with a focus on ... market. A comparison between the international and Chinese ...
(Date:7/25/2014)... Philadelphia, PA (PRWEB) July 25, 2014 ... that Valerie D. Weber, MD, MS, FACP, has been appointed ... , Weber will join Drexel from The Commonwealth Medical College, ... Sciences, associate dean for clinical affairs, and professor of medicine. ... of The Commonwealth Medical College, Weber had a major role ...
(Date:7/25/2014)... workers, especially men, may be at higher risk for type ... new study suggests. Also at special risk are shift ... moving around at various times of the day. The ... Alan Manevitz, a clinical psychiatrist at Lenox Hill Hospital in ... shifts disrupts many key body chemicals, creating a ripple effect ...
(Date:7/25/2014)... --, Treatment for lymphoma may lower men,s fertility, new ... which are cancers of the body,s white blood cells, ... reproductive years. For men, treatment for these cancers can ... their fertility within two years of treatment, the researchers ... of this significant side effect before treatment begins. ...
Breaking Medicine News(10 mins):Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2
... ALEXANDRIA, Va., Feb. 12 An article published in ... the American Medical Association helps physicians to better ... determine which end-of-life care options may be best for ... life have increased in recent years. With more ...
... Calif., Feb. 12 Fisher Vista, LLC, a marketing,and ... human resource,industries today announced that Kevin Grossman, who has ... president of its HRmarketer.com division. , ... overall responsibility of,HRmarketer.com and the HRmarketer Services Group. ...
... BASKING RIDGE, N.J., Feb. 12 Regado Biosciences, ... President and Chief Executive Officer, will be presenting ... Philadelphia, PA on Friday, February 20, 2009, at ... a review of the Company,s lead development product, ...
... of prescribing system to avoid ,alert fatigue, , , ... override electronic medication safety alerts and rely instead ... patients, which suggests that physicians find the alerts ... , Researchers looked at the electronic prescriptions ...
... 2009 Oral-B(R) Stages, the dental,professional,s #1 recommended ... a campaign in recognition of National Children,s Dental ... about the state of children,s,oral health in America, ... parents and,healthcare providers alike. In fact, tooth ...
... 12 Kovarus, Inc., a premier,technology consulting firm, and ... today jointly announced the launch of a new bike ... awareness of a good cause,the American Brain Tumor Association ... http://www.newscom.com/cgi-bin/prnh/20080708/AQTU138LOGO ) , The Studio ...
Cached Medicine News:Health News:JAMA Article Provides Guidance to Physicians on End-of-Life Care 2Health News:Kevin Grossman Named President of HRmarketer.com 2Health News:Docs Override Most Electronic Drug Warnings 2Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 2Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 3Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 4Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 5Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 6Health News:Biking for Fun, Sport, and Brain Tumor Awareness 2Health News:Biking for Fun, Sport, and Brain Tumor Awareness 3
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid Yeast Plus, a microbial identification system....
IDS Rapid NH, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: